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Background
Although cytotoxic CD8 T lymphocytes (CTL) were
historically considered primary effectors of antitumor
immunity, solely boosting CTL responses with CD8 vac-
cines in various tumor types has yielded unpredictable
clinical results, possibly because CTLs function subopti-
mally without adequate CD4 T lymphocyte help. CD4
T-helper type 1 (Th1) cells secrete INF-g/TNF-a, inducing
tumor senescence and apoptosis. As such, successful
incorporation of CD4 epitopes into cancer vaccine con-
struction and generation of durable antigen-specific CD4
immunity remains a challenge. Using the extracellular
domain (ECD) of HER3 as a candidate “oncodriver” tumor
antigen, we sought to identify immunogenic HER3 pep-
tides that demonstrate Class II promiscuity and generate
anti-HER3 CD4 immunity for inclusion in vaccine
development.
Methods
A library comprising 123 overlapping 15 amino acid-
long peptide fragments was generated from the HER3-
ECD. Autologous monocyte-derived DCs from donors
were matured to a type 1-polarized (DC1; IL-12 secret-
ing) phenotype, and pulsed with HER3-ECD. Harvested
DC1s were co-cultured with purified CD4 T cells. After
10 days, sensitized CD4 T cells were restimulated
against immature DCs (iDC) pulsed with HER3 library
peptide clusters or irrelevant CD4 peptide control. Th1
responses, measured by IFN-g ELISA, were considered
antigen-specific if IFN-g production was at least twice
that of irrelevant control.
Results
Th1 sensitization was initially performed in 5 breast
cancer patients with known anti-HER3 reactivity in order
to identify single immunogenic HER3 CD4 epitopes. To
achieve this, HER3 ECD-specific CD4 Th1 were sequen-
tially restimulated against 10-peptide clusters, narrowed to
3-peptide clusters, and ultimately to single immunogenic
HER3 peptides. A representative peptide screen is depicted
in Figure 1. Four immunogenic peptides - HER3(51-75),
HER3(402-417), HER3(417-432), HER3(451-465) - were
reproducibly identified and promiscuous across HLA-DR,
DP, and DQ subtypes. When Th1 cells from 4 non-HER3
reactive donors were sensitized using DC1s pulsed with
the four identified HER3 peptides, and subsequently chal-
lenged to recognize HER3 ECD-pulsed iDCs, all donors
demonstrated successful sensitization not only to indivi-
dual immunogenic HER3 peptides, but also recognized
native HER3-ECD.
Conclusions
DC1 pulsed with an overlapping tumor antigen-derived
peptide library can identify promiscuous class II peptides
for CD4 T cell vaccine development. In this study, immu-
nogenic HER3 CD4 peptides effectively overcome immune
tolerance to self-tumor antigens. Utilization of these HER3
CD4 peptides in vaccine construction warrants investiga-
tion in patients harboring HER3-overexpressing cancers.
Additionally, these results represent a novel strategy to
rapidly and reproducibly identify class II-promiscuous
immunogenic CD4 epitopes from any tumor antigen for
cancer immunotherapy using a DC1-Th1 platform.
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Figure 1 Representative peptide screen.
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